Drug Profile
Research programme: antifungals - Eli Lilly and Company/Phytera
Latest Information Update: 23 Jan 2007
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Phytera
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 22 Jan 2007 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 30 Jan 2001 Preclinical development for Mycoses in USA (Unknown route)